Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methylphenidate extended release - Highland Therapeutics

Next Previous
Drug Profile

Methylphenidate extended release - Highland Therapeutics

Alternative Names: Benjorna; HLD-200; JORNAY PM; Methylphenidate delayed release; Methylphenidate hydrochloride extended release

Latest Information Update: 26 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Highland Therapeutics
  • Developer Collegium Pharmaceutical; Highland Therapeutics; Ironshore Pharmaceuticals (America) Inc
  • Class Behavioural disorder therapies; Neuroprotectants; Nootropics; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Central nervous system stimulants; Dopamine uptake inhibitors; Monoamine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 08 May 2025 Launched for Attention-deficit hyperactivity disorder (In children) in Canada (PO) (prior to May 2025)
  • 14 Nov 2024 Registered for Attention-deficit hyperactivity disorder (In children) in Canada (PO)
  • 13 Sep 2024 Phase-III clinical trials in Attention-deficit hyperactivity disorder (In children) in USA (PO) (NCT06431256)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top